Acorda Therapeutics (ACOR) : Traders are bullish on Acorda Therapeutics (ACOR) as it has outperformed the S&P 500 by a wide margin of 8.19% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 10.32%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 10.91% in the last 1 week, and is up 6% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 6.56% and the 50-Day Moving Average is 5.82%.The 200 Day SMA reached 12.8% Acorda Therapeutics, Inc. is up 2.29% in the last 3-month period. Year-to-Date the stock performance stands at -38.43%.
Acorda Therapeutics (ACOR) : The consensus price target for Acorda Therapeutics (ACOR) is $42.67 for the short term with a standard deviation of $17.5. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $60, however, the pessimist price target for the company is $25.
Company shares have received an average consensus rating of Hold for the current week Acorda Therapeutics (NASDAQ:ACOR): The stock opened at $25.68 and touched an intraday high of $26.42 on Friday. During the day, the stock corrected to an intraday low of $25.34, however, the bulls stepped in and pushed the price higher to close in the green at $26.34 with a gain of 2.45% for the day. The total traded volume for the day was 942,892. The stock had closed at $26.34 in the previous trading session.
Acorda Therapeutics, Inc. is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10milligrams, a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders, including chronic post-stroke walking deficits (PSWD), Parkinsons disease, epilepsy, heart failure, MS, and spinal cord injury.